Synovial sarcoma is a rare, aggressive cancer with limited treatment options. Tecelra, the first T-cell receptor (TCR) gene therapy approved in the U.S., marks a major breakthrough by engineering patients’ T-cells to target tumor antigens. It has shown promising responses in advanced cases, offering new hope and advancing precision cancer therapy.

<h2>What Is Rhabdomyosarcoma?</h2><p><strong>Rhabdomyosarcoma (RMS)</strong> is the <strong>most common soft tissue sarcoma in children and adolescents</strong>, accounting for approximately <strong>3%–4% of all childhood cancers</strong> and approximately <strong>350 new cases per year</strong> in the United States. RMS arises from <strong>primitive mesenchymal cells</strong> that normally give rise to skeletal muscle, though it can occur in sites that lack skeletal muscle (e.g., bladder,...

<h2>What Is Leiomyosarcoma?</h2><p><strong>Leiomyosarcoma (LMS)</strong> is the <strong>second most common soft tissue sarcoma</strong>, arising from <strong>smooth muscle cells</strong>. It can develop virtually anywhere in the body where smooth muscle is present — most commonly the <strong>uterus, retroperitoneum, and major blood vessel walls</strong>. LMS is broadly categorized into two major subtypes: <strong>uterine LMS (uLMS)</strong> and <strong>soft tissue / retroperitoneal LMS...